Drugs & Therapy Perspectives

, Volume 20, Issue 2, pp 19–22 | Cite as

Cannabinoids courting attention because of their potential in CNS disorders

Disease Management


Multiple Sclerosis Ondansetron Trigeminal Neuralgia Anandamide Rimonabant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003; 17: 179–202.PubMedCrossRefGoogle Scholar
  2. 2.
    Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000; 60: 1303–14.PubMedCrossRefGoogle Scholar
  3. 3.
    Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001; 178: 107–15.PubMedCrossRefGoogle Scholar
  5. 5.
    Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38: 44–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Sieradzan KA, Fox SH, Hill M, et al. Cannabinoids reduced levodopa-induced dyskinesiain Parkinson’s disease: a pilot study. Neurology 2001; 57: 2108–11.PubMedCrossRefGoogle Scholar
  7. 7.
    Knoller N, Levi L, Shoshan I, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled phase II clinical trial. Crit Care Med 2002; 30: 548–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Notcutt WG, Price M, Chapman G. Clinical experience with nabilone for chronic pain. Pharm Sci 1997; 3: 551–5.Google Scholar
  9. 9.
    Campbell FA, Tramer MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain?: a qualitative systematic review. BMJ 2001; 323: 13–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323: 16–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987; 79: 946–52.PubMedGoogle Scholar
  12. 12.
    Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83 (4): 637–49.PubMedCrossRefGoogle Scholar
  13. 13.
    Penta JS, Poster DS, Bruno S, et al. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. J Clin Pharmacol 1981; 21 (8–9 Suppl.): 11S–22SPubMedGoogle Scholar
  14. 14.
    Pope H, Gruber A, Yurgelan-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend 1995; 38: 25–34.PubMedCrossRefGoogle Scholar
  15. 15.
    Ries RK. The dually diagnosed patient with psychotic symptoms. J Addict Dis 1993; 12 (3): 103–22.PubMedCrossRefGoogle Scholar
  16. 16.
    Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 1976; 282: 221–39.PubMedCrossRefGoogle Scholar
  17. 17.
    Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 1998; 30 (2): 187–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Robbe H. Marijuana’s impairing effects on driving are moderate when taken alone but severe when combined with alcohol. Hum Psychopharmacol Clin Ther 1998; 13: S70–80.CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations